Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 1999

View Archived Issues

New treatment strategy successful in patients with severe CHF

Cancer therapeutics joint venture IBC Pharmaceuticals receives start-up funding

Toprol-XL effective in heart failure; MERIT-HF trial results presented

Long-term treatment with phen-fen associated with valvular abnormalities

Eptifibatide lowers MI incidence, heart muscle injury in ACS patients

Telomeres and telomerase linked to cancer, age-related changes

Pliva and Althexis collaborate on structure-based design of new antibiotics

New DAG analogues acting as PKC agonists or antagonists

Zeria patents new series for BPH

New patent issues covering Cytoclonal's novel methods of producing paclitaxel

Orally active analgesic agents in development at Otsuka

N-type calcium channel inhibitors described by Ono

GABA-A receptor ligands from MS&D for Alzheimer's disease

Volunteer study suggests that CMI-977 may be superior to zileuton in both efficacy and safety

New market introduction for Seretide

Kanebo's Na+/H+ exchange inhibitor is a promising treatment for acute coronary syndrome

Venous responsiveness to NE is enhanced in the presence of aspirin

BTG licenses anti-CD3 antibody to LeukoSite

Health Canada approves Rebetron for chronic HCV

FDA grants priority review status, sets date for advisory committee review of Actos

Spanish market introduction announced for antirejection MAb

SkyePharma completes DepoTech acquisition

Hollis-Eden to initiate HIV/AIDS trials with HE-2000 in South Africa

Improvement in seasonal allergic rhinitis following preventive treatment with rhuMAb-E25

Effexor XR receives FDA approval for treatment of GAD

CysLT1 antagonists show potential as Rx for chronic urticaria

Hemosol to begin multinational phase III trials of Hemolink

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...